We have analyzed the V/~ usage by CD4 + and CD8 + T cells from human immunodeficiency virus (HIV)-infected individuals in response to an in vitro stimulation with the superantigenic erythrogenic toxin A (ETA) of Streptococcus ivogenes. ETA amplifies specifically CD4 + and CD8 + T ceils from control donors expressing the V~8 and the VB12 dements. When peripheral T ceils from asymptomatic HIV-infected individuals were stimulated with ETA, there was a complete lack of activation of the V/~8 + T cell subset, whereas the V~12 + T cell subset responded normally to the superantigen. This V~-specific anergy, which was also observed in response to staphylococcal enterotoxin E (SEE), affected both CD4 + and CD8 + T cells and represented an intrinsic functional defect rather than a specific lack of response to bacterial superantigens since it was also observed after a stimulation with V//8 monoclonal antibodies. The V/~8 anergic T ceils did not express interlenkin 2 receptors (IL-2Rs) and failed to proliferate in response to exogenous IL-2 or IL-4, suggesting that this anergy was not a reversible process, at least by the use of these cytokines. The unresponsiveness of the V~8 T cell subset is frequent since it was found in 56% of the patients studied, and comparison of the clinical status of responder vs. anergic patients indicated that the only known common factor between them was HIV infection. In addition, it is noteworthy that the anergy of the V~8 subset may be a very early phenomenon since it was found in a patient at Centers for Disease Control stage I of the disease. These data provide evidence that a dominant superantigen may be involved in the course of HIV infection and that the contribution of HIV has to be considered.
S
ome infectious agents such as pathogenic bacteria and retroviruses seem to have evolved towards a similar strategy to influence the immune system of the host and to facilitate infection, by expressing molecules that have features of superantigens. Exogenous bacterial superantigens comprise a set of protein toxins produced by Staphylococcus, Streptococcus, or Mycoplasraa that are recognized, in the context of MHC class II molecules, by T cells expressing particular TCR V~ gene families, causing strong T cell activation associated with toxic shock and autoimmune diseases (1) (2) (3) (4) (5) . The immunological properties of bacterial superantigens are reminiscent of the Mls antigens that were shown to be encoded by the 3' open reading frame of mouse mammary tumor virus and were responsible for the activation and subsequent deletion of CD4 + T ceil subsets expressing V~ dements that react with this retroviral superantigen (6) (7) (8) (9) (10) . Involvement of superantigens in the pathogenesis of murine infections was also Part of this work has been presented in a preliminary report as a letter to the editor (1993. Lancet. [50] [51] .
reported with a variant of MuLV encoding for a truncated gag fusion protein which possessed superantigenic properties and was shown to be responsible for the routine acquired immunodeficiency syndrome (11) (12) (13) .
Since HIV-1 is a retrovirus, and since the pathology of HIV infection and AIDS involves predominantly the same CD4 + T cells that are commonly involved in superantigenassociated phenomenons, it was suggested that HIV might cause, in conjunction with dass II genes, cell anergy and depletion of noninfected CD4 + T cells bearing TCR Vfl determinants, by encoding a superantigen expressed by activated infected cells (14) . Recent studies (15) (16) (17) reported significant perturbations of the TCR Vfl repertoire in HIV-infected subjects, suggesting the contribution of superantigens in AIDS pathogenesis.
In vivo studies of peripheral tolerance using either Mls antigens or bacterial enterotoxins have shown that after expansion of T cells bearing the cognate Vfl determinants, the remaining T cells are unresponsive to restimulation by the super'antigen in vitro (T cell anergy) (18) (19) (20) (21) . Therefore, anergy of a given Vfl T cell subset gives evidence of a previous acti-vation of this subset by a superantigen. We have used the streptococcal erythrogenic toxin A (ETA) 1 (22) to analyze the VB usage of peripheral T cells from asymptomatic HIVinfected subjects in response to this superantigenic activation. Our data indicate the existence, in a large fraction of infected individuals, of a V~-specific anergy affecting both CD4 + and CD8 + T cells that express the VB8 TCR element. We have characterized this V~/-specific anergy and have shown that it was not restricted to an ETA stimulation but represented an intrinsic functional defect. The precocity of this phenomenon and the absence of correlation with previous viral or bacterial opportunistic infections suggest the involvement of an HIV-associated superantigen.
Materials and Methods
Blood Samples. Analysis of the V~ usage by CD4 + or CD8 + T cells from HIVinfected or control individuals in response to a superantigenic activation was performed with the same staining procedure as described above. FACS | analysis of double-stained activated cells was performed simultaneously on two gated populations, e.g., the K1 population corresponding to small cells and the R2 population corresponding to blastic cells (see Fig. 1 ). To accurately compare, between different donors, T cell subpopulations bearing a given V~ after in vitro activation, results were calculated as the percentage of T cell blasts bearing a particular V~ after stimulation divided by the percentage of T cells bearing that Vfl before stimulation. Analysis of IL-2K (CD25) expression on V~ + T cell subpopuhtious consecutively to ETA stimulation was performed as described above, but was restricted to the K1 population (small cells) to allow comparison between the group of anergic HIV-infected donors and groups of responder HIV-infected donors and controls. The MannWhitney U test was used to compare the different groups of individuals. ~ ~"'"'" " 1.00~.
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Vj88-and V~12-specific Stimulation of Peripheral Human T Cells by ETA.
Streptococcal ETA is a potent superantigen (22, 24) . In vitro activation of PBMC from control donors by ETA leads to blastogenesis easily identified by FACS ~ analysis. Two populations (K1 and R2) can be distinguished considering both the size (FSC) and the granulosity (SSC) of activated ceils (Fig. 1 B) : blastic cells (gate R2) appear larger and more granular than nonblastic cells (gate R1), the latter exhibiting size and granulosity ofex vivo, nonstimulated lymphocytes (Fig. 1A) . Analysis of the VB usage by CD4 + and CD8 + T calls responding to ETA was performed with Abs against members of the VflS, V~8, and V/312 families. Fig. 1 , J to G and K to H). By contrast, T cells expressing VB5 were especially found in the nonblastic R1 population (Fig. 1 F) . These same results were found for the CD8 § T cell population ( Fig. 1 M) , confirming previous studies indicating that, in vitro, both CD4 + and CD8 + T ceils are stimulated by ETA (22, 25) .
To adequately compare among different donors, T cell subpopulations bearing a given V~ after ETA stimulation, results were calculated as the percentage of T cell blasts bearing a particular V~ after stimulation divided by the percentage of T ceils bearing that V~ before stimulation. This calculation, proposed initially by Kappler et al. (1) was designed to correct for variations in V~ expression from one person to another. In addition, it allowed one to visualize an amplification of a given V~ T cell subset after stimulation, namely when the index was superior to 1. This calculation was always used throughout this study.
The ratio of T ceils bearing a particular V/~ before ( Figure 2 . V/~-specitic stimulation of CD4 + and CD8 + T cells from HIV-infected donors. PBMC from HIV-infected donors were stimuhted by ETA as described in Fig. 1 . Anal)sis of V/3 usage of CD4+ and CD8 + T cells in response to ETA and index calenlation were performed as described in Fig. 1 . Results of a representative experiment are shown.
1, C-E) and after culture in the absence of stimulation (in medium alone) was close to 1 (Fig. 1, L and M) . In contrast, it was dear that T cells bearing Vfl8 and Vf112 were enriched in blasts produced by activation with ETA (ratio 4, 4 and 4, 1, respectively for CD4 + T cells and 2,3 and 2,5 for CD8 + T cells), whereas T cells bearing Vfl5 were specifically excluded from the ETA blasts (ratio '~0.22). Indeed Vfl5 + T cells remained in the R1 nonblastic population. The enhanced ratio observed for this latter population does not correspond to a specific proliferation, but rather is a consequence of an apparent enrichment of the R1 population with Vfl5 + cells due to the disappearance from this population of the other subsets (Vfl8 + and Vf112+) (Fig. 1, L and M).
Analysis of the V~ Usage by CD4 + and CD8 + T Cells from HIV-infected Patients in Response to ETA
Stimulation. An extensive study of the Vfl usage of patients' T cells responding to ETA (summarized in Table 1 ) was performed in HIVinfected patients, most of which were asymptomatic at the beginning of this study. Experiments performed as described in Fig. 1 and index of Vfl stimulation calculated as mentioned above revealed that HIV-infected patients could be divided into two groups. The first, named "responder;' is represented by the patient FY in Fig. 2 . The Vfl + T ceU subsets of these patients behaved as did those of the controls (Fig. 1) to a stimulation by ETA with a specific activation of the Vfl8 + and VB12 + subsets among CD4 + (Fig. 2 A) and CD8 + (Fig. 2 B) T ceUs. The second, named "anergic" represented by the patient ME in Fig. 2 , showed a Vfl8-specific lack of response to ETA stimulation: the majority of Vfl8 + T cells were found in the small cell population (population R1). Indeed, after ETA stimulation, the indexes of Vfl8 + T cell in the blasts were around or below 1 in contrast to those of Vf112 + T cells which could reach 6-8 in the blasts of the same patient ( Fig. 2 and Table 1 ). The fact that the Vfl8 + T cells did not disappear after ETA stimulation but remained in the small cell population (R1) indicated the existence of an anergic state in this subset rather than a specific deletion. Fig. 2 shows that this Vfl-specific anergy was found in both CD4 + and CD8 + T cells. Table 1 summarizes the results from a series of experiments performed with lymphocytes from 43 HIV-infected patients and 15 seronegative donors. Interestingly, a large fraction of HIV-infected patients showed a Vfl8-specific anergy in response to ETA since it concerned 56 % of the patients studied (24 over 43). This phenomenon was never observed in lymphocytes from seronegative controls, including a patient infected by EBV infectious mononucleosis (MNI) ( Table 1) . This anergy was not associated with a general unresponsiveness to ETA, since all the patients from the nonresponcler group showed a normal expansion of the Vf112 T cell subset in response to ETA, and the corresponding mean index in T cell blasts was comparable to that of the responder group. By contrast, the absence of amplification of the Vfl8 + T cell subset in ETA-stimulated cultures from anergic patients was underlined by a mean index below 1 in T cell blasts as compared to 3.5 for the two other groups, responders and controls (Table 1) PBMC from a control donor or from HIV-infected patients belonging either to the responder or to the anergic group were stimulated for 4 d with ETA (1/~g/ml) or 11 d with SEE (1 tzg/ml), rIl.,2 (20 U/ml) was added at day 3 in SEE-stimulated cultures. Analysis of Vfl usage of CD4 § T cells in response to these superantigens and index calculation were performed as described in Fig, 1 . Results of a representative experiment are shown.
be a very early phenomenon since it was found in a patient at CDC stage I of the disease (see Table 1 ). Thus it appeared that the only known common factor between patients in all groups was HIV infection.
Vfl8-specific Unresponsiveness Is Not Restricted to an ETA Stimulation but Represents an Intrinsic Functional Defect.
Since unresponsiveness of the V~8 T cell subset could be the consequence of a specific defect in the interaction between this subset and streptococcal ETA, we analyzed the response to another bacterial superantigen, SEE. In addition to stimulating T cell subsets expressing the V~5.1, V~36, and VB18 dements, SEE activates also the VB8 + T cell subset (1, 26) . Comparison of the in vitro SEE and ETA stimulation on the expansion of the VB8 CD4 + T cell subset from the two groups of patients is shown in Fig. 3 . No amplification of the V~8 T cdl subset was observed after SEE stimulation of lymphocytes from a nonresponder patient, whereas in the same culture, the expected amplification of the VB5.1 subset occurred. The same results were observed in the CD8 + T cell subpopulation (data not shown), although the SEE-activated population which was predominantly CD4 + blast cells in response to SEE, is composed of 90% CD4 + and 10% CD8 + T cells as compared to 50% CD4 + and 50% CD8 + T cells in response to ETA. A comparison of SEE and ETA stimulations on lymphocytes from eight patients from the anergic group confirmed that the anergy was never found in the VBS.1 and V/312 subsets (data not shown).
To confirm that the VB-specific anergy was not only associated to a superantigenic activation but rather represented an intrinsic functional defect, stimulations were performed with anti-V~ mAbs and compared to those induced by ETA and SEE. Table 2 shows a representative experiment in which T ceils from three responder patients were significantly stimulated by coated anti-VB8 mAbs, as well as by anti-V~5.1 and anti-V1312 mAbs. On the contrary, T cells from three anergic patients were not sensitive to anti-V~8 stimulation whereas they were normally stimulated by anti-V~12 and anti-VBS.1 mAbs. As expected, the VB8-specific anergy was also observed in response to ETA and SEE, each superantigen representing a control of the mAb stimulation since SEE activated V/35.1 and VB8 subsets whereas ETA activated VB8 and V/312 subsets. Thus, the anergic state observed in response to superantigens was specific and intrinsic to the V~8 T cell subset.
Anergic Vj88 T Cells Do Not Express IL-2Rs and Are Unresponsive to Exogenous
Cytokines. In vivo administration of the superantigen staphylococcal enterotoxin B (SEB) (19) (20) (21) or immunization of Mls-1 b mice by Mls-1 a spleen cells (18) have been reported to induce in mice a peripheral T cell tolerance characterized by the anergy of T cell subsets expressing specific VI3 determinants. In these models, the anergic subset expressed the IL-2gs partially (19) or normally (18) , but failed to respond to exogenous IL-2 (18, 19, 27) . Since our results suggest the induction, in the course of HIV infection, of a VB-specific peripheral tolerance, we analyzed whether the IL-2/IL-2Rs pathway was affected in the V~8 anergic subset.
IL-2gs (CD25) expression was studied on the V~5, Vr and V~12 subsets after 4 d of stimulation with ETA. To compare the V~8 anergic subset to the others, CD25 expression was analyzed on the R1 (small cells) population. Results in Fig. 4 show that ETA stimulation induced the expression by ETA (1 /~g/ml) in the absence or in the presence of dD2 (20 U/ml) or rIL-4 (4 ng/ml). Analysis of Vfl usage of CD4 + and CD8 + T cells in response to ETA stimulation and index calculation were performed as described in Fig. 1 . Results of this experiment are representative of a number of fimilar experiments performed on anergic and responder patients.
of IL-2tLs on a high percentage of small T cells expressing V312 element in the three groups of donors, indicating that expression of IL-2Rs precedes blastogenesis. Although a dispersion of CD25 expression among donors was noticed (probably due to an asynchronous activation), no signiiicative difference in the V/~12 subset was found between controls (C), responder (R), and nonxesponder (NR) groups. By contrast, CD25 expression by the anergic V38 subset was very low for all the nontesponder patients and a significant difference (p <0.001) was found between the anergic group and the two other groups (Fig. 4) . h is noteworthy that the anergic V/$8 subset behaves like the V35 subset from the three groups, this latter subset being insensitive to ETA activation (Fig. 4) .
Addition of rIL-2 at the initiation of ETA stimulation could not reverse the anergic state of the V38 subset (Fig. 5) . Similar results were obtained with a crude preparation of cytokines (TCGF) (data not shown). The influence of IL-4 was also studied since a recent study indicated that infection of SEBtolerant mice with NiFpostrongylus brasiliensis (known to induce a high IL-4 secretion in normal mice) circumvented the anergy of the CD4 +V38 + T cells (28) . Fig. 5 shows that the V3-specific anergy observed in the course of HIV infection could not be reversed by IL-4.
Discussion
Peripheral tolerance, due either to T cell deletion or anergy, plays a major role in the suppression of autoimmunity (29, 30) . Whereas deletion has been convindngly demonstrated for immature T cells recognizing sdf-determinants during thymic development (29, (31) (32) (33) , functional anergy has been recently demonstrated for peripheral T cells exposed to superantigens in vivo. Thus, murine T cells bearing V/36 + TCR, specific for determinants encoded by the Mls-l' locus, are rendered unresponsive to MIs-P in vitro after prior exposure to Mls-l~-bearing cells in vivo (18, 27, 34) . Similarly, V38 + T cells no longer respond in vitro to SEB when taken from SEB-primed mice (19) (20) (21) 35) . In this report, we show the existence, in an important fraction of HIV-infected individuals, of a V3-specific clonal anergy that affects both CD4 + and CD8 + T cells. The V38-specific unresponsiveness we observed in response to streptococcal superantigen ETA was not the consequence of a defective presentation of ETA since in the same cultures, the V312 + population was always normally stimulated by this antigen. In addition, the V~8 anergy was also observed in response to another bacterial superantigen, SEE. The failure of anti-V38 mAbs to stimulate this subset indicates that this V3-specific anergy represents an intrinsic functional defect rather than a specific lack of response to certain bacterial superantigens.
Inactivation or ddetion of superantigen-reactive T cells by acute confrontation with superantigen is preceded by specific activation of these cells (35) (36) (37) . Several recent reports have discussed attempts to indirectly reveal the presence of an HWassociated superantigen by looking for consistent amplifications and/or deletions in the peripheral TCR V3 repertoire of HIV-infected individuals. A more restricted V/3 repertoire (V/~14 through V/320 appeared to be deleted) was found in HIVqnfected patients with advanced disease (15) and a significant increase of peripheral CD4 + T cells of the V35.3 subfamily was reported in asymptomatic subjects (16) . Perturbations in the V3 repertoire were also found in several pairs of monozygotic twins discordant for HIV with identical MHC (17) , allowing meaningful comparisons of their V3 repertoire, since one of the major factors that influence the nature of the peripheral TCR VB repertoire is the MHC class II haplotype of the individual (38) . Our study provides evidence that a dominant superantigen may be involved early in the course of HIV infection.
Since in mice in vivo administration of a superantigen induces, in addition to clonal anergy, varying degrees of clonal deletion (2, 18-21, 36, 39, 40) , we compared ex vivo VB8 expression by CD4+ and CD8+ T cells from anergic subjects to that of responder and control subjects, but we could not detect any deletion or underrepresentation of this subset in anergic patients (mean values: 4.95% V/~8+CD4 + +-1.90; 4.03% VB8+CD8 + + 1.88 in nonresponders vs. 4.24% V/58+CD4 + + 1.26 and 4.04% V~8+CD8 + + 2.17 in responders). Clonal deletion, however, is not an obligatory consequence of anergy induction and anergized cells may persist for extended periods of time (18, 27, 36) . In addition, the outbred nature of human populations is an important obstacle to an accurate comparison of V/5 repertoires.
In vitro models of T cell anergy suggest that a major defect in these cells is their inability to produce IL-2, whereas anergized cells are fully responsive to exogenous IL-2 (41). Models of in vivo-induced anergy (18, 19, 21, 27, 37 ) and the present data, suggest a more profound defect. Upon in vitro restimulation with ETA, anergic VB8 + T cells from HIV-infected individuals do not express IL-2Rs at all. These cells are also unresponsive to exogenous IL-2 or IL-4. It suggests that unresponsiveness of the anergized V~8 § T cells appearing in the course of HIV infection is not a reversible process, at least by the use of these cytokines. Indeed, a 1-yrlongitudinal study of HIV-infected subjects belonging to responder or anergic group indicates that the V/3 anergic status is not a transient phenomenon, which may reflect a chronic exposure to the superantigen.
Several observations are in favor of a direct involvement of HIV in the V~-specific anergy observed in asymptomatic HIV-infected individuals: (a) anergy can be observed very early in the course of HIV infection e.g., in T cells from a primo-infected patient (CDC stage I); (b) comparison of the clinical status of responder vs. anergic patients showed no correlation with previous viral or bacterial infections, suggesting that anergy may not be induced by opportunistic pathogens; (c) inactivated HIV is able to induce, in vitro, a strong proliferation of normal peripheral lymphocytes and, concomitantly, the sdective expansion of the V~8 + T cdl subset is reproducibly detected (Poccia, F., and M. L. Gougeon, manuscript in preparation).
Except for the acute pathogenic variant of simian immunodeficiency virus PBj14 (42) , no report has shown until now the ability of HIV to activate normal peripheral T cells. Since a selective expansion of superantigenic-reactive T ceils is known to precede anergy, one can speculate that in vivo infection of CD4 + ceils will release viral protein(s) containing Vfl-specific dements and presentation of this superantigen to T cells, in association with MHC class II molecules, will induce activation followed by anergy of subsets bearing the cognate Vfl determinants. It is interesting to note that the putative viral superantigen involved in this process has no sdective tropism for CD4 + T cells, since both CD4 + and CD8 + T cells are found to be anergic in patients. A recent report (43) described the dependence of HIV-1 replication on a superantigen and it concerned particularly the Vf112 § CD4 § cell subset which replicated more e~ciently HIV in vitro and which was found enriched for gp120-expressing cells in vivo. Our study is probably concerned with another superantigen, since the Vfl specificity involved is different and its mode of action also may be different since we never found a Vfll2 anergy in patients' peripheral T cells. The fact that Vfl8 anergy is not observed in all HIV-infected individuals but in 56% of them may be related to at least two factors: the dependence of the HLA-DR phenotype of presenting cells for the ef~cacy of the putative superantigen (38, 44, 45) , and the possible requirement, for the acquisition of super'antigenic activity, of mutations in the viral protein.
The involvement of superantigeus has been recently suggested in autoimmune diseases such as rheumatoid arthritis (46) or multiple sclerosis (5, 47) and the expansion oft cells expressing TCR Vfl2 and Vfl8 has been reported in patients in the acute phase of Kaw saki disease (48) . The influence of a superantigen in these pathologies was suggested by enhancement of T cell subsets expressing given VB dements or by skewed TCR repertoire. Our study reports for the first time in humans a specific V~ anergy associated with a retroviral infection. It is unclear what role a viral superantigen may play in rendering target T ceils anergic or susceptible to deletion by apoptosis (49) (50) (51) (52) . Activation of a significant fraction of CD4 cells by a superantigen would greatly increase the number of cells susceptible to virus infection and replication (43), contributing to viral dissemination and progressive immune failure. Encoding for superantigenic protein would also help the virus to escape from the immune system by inducing anergy in CD8 + cytotoxic T ceUs that kill infected cells. Thus an as yet unidentified HIV-l-encoded superantigen could contribute, in addition to other cytopathogenic mechanisms, to the profound immunodeficiency observed in HIV infection.
